The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug
Business Insider -

The decision to approve Aduhelm has raised concerns and led three advisors to resign. The agency's head is now asking for an outside investigation.

Read this story at


Related Articles